13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
42 檔
33.7%
As reported in its official Q1 2026 Form 13F filing, Sector Gamma As's tracked investment portfolio stood at $461.0M with 42 total positions.
Sector Gamma As executed strategic sector rebalancing during Q1 2026, establishing 11 new positions while fully exiting 5 holdings and trimming 16 positions.
In terms of portfolio concentration, the top 5 core holdings (including BMY, MRK, PFE) accounted for 33.7% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 11.86% | -2.78% | +10.99% | |
| 2 | MRK | Merck & Co. Inc. | Stock-Healthcare | 7.39% | -1.34% | -28.41% | |
| 3 | PFE | Pfizer Inc | Stock-Healthcare | 7.24% | -1.99% | +26.97% | |
| 4 | MDT | Medtronic plc | Stock-Healthcare | 5.74% | +0.24% | +4.09% | |
| 5 | INCY | Incyte CORP | Stock-Healthcare | 4.46% | -0.26% | -8.35% | |
| 6 | AMGN | Amgen Inc | Stock-Healthcare | 3.92% | -1.86% | -22.64% | |
| 7 | BIIB | Biogen Inc | Stock-Healthcare | 3.90% | -1.36% | +5.41% | |
| 8 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 3.33% | -0.67% | +17.63% | |
| 9 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.20% | +0.46% | +20.86% | |
| 10 | BDX | Becton Dickinson And Co | Stock-Healthcare | 3.07% | -0.01% | -37.59% | |
| 11 | ELV | Elevance Health Inc | Stock-Healthcare | 3.04% | +0.69% | +35.08% | |
| 12 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.00% | +0.26% | -8.38% | |
| 13 | CAH | Cardinal Health Inc | Stock-Healthcare | 2.74% | -0.64% | -11.38% | |
| 14 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.33% | -2.33% | EXIT | |
| 15 | CVS | Cvs Health CORP | Stock-Healthcare | 2.30% | +1.19% | -23.80% | |
| 16 | BRKR | Bruker CORP | Stock-Healthcare | 2.17% | -0.18% | -0.27% | |
| 17 | GEHC | GE Healthcare Technology | Stock-Healthcare | 2.12% | +0.77% | +10.51% | |
| 18 | ABT | Abbott Laboratories | Stock-Healthcare | 2.12% | +0.78% | — | |
| 19 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.75% | -1.75% | EXIT | |
| 20 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 1.67% | -1.67% | EXIT | |
| 21 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.62% | +1.65% | — | |
| 22 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.58% | -0.43% | +13.47% | |
| 23 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.56% | +0.56% | — | |
| 24 | QGEN | Qiagen N.V. | Stock-Healthcare | 1.54% | +0.90% | — | |
| 25 | AVTR | Avantor Inc | Stock-Healthcare | 1.29% | +0.66% | — | |
| 26 | CNC | Centene CORP | Stock-Healthcare | 1.26% | +1.00% | -37.08% | |
| 27 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.21% | -0.34% | — | |
| 28 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.21% | +0.56% | +21.12% | |
| 29 | LH | Labcorp Holdings Inc | Stock-Healthcare | 1.20% | +0.38% | -29.61% | |
| 30 | ASND | Ascendis Pharma A/S | Stock-Other | 1.15% | -1.15% | EXIT | |
| 31 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.14% | +0.05% | -37.34% | |
| 32 | DXCM | Dexcom Inc | Stock-Healthcare | 0.83% | +0.66% | -26.27% | |
| 33 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.81% | +0.12% | -18.09% | |
| 34 | KURA | Kura Oncology Inc | Stock-Other | 0.79% | +0.24% | -9.66% | |
| 35 | HUM | Humana Inc | Stock-Healthcare | 0.79% | -0.79% | EXIT | |
| 36 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.78% | -0.78% | EXIT | |
| 37 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.75% | +0.12% | — | |
| 38 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.74% | -0.74% | EXIT | |
| 39 | ARDX | Ardelyx Inc | Stock-Other | 0.73% | +0.03% | — | |
| 40 | COGT | Cogent Biosciences Inc | Stock-Other | 0.73% | -0.73% | EXIT | |
| 41 | OGN | Organon & Co | Stock-Healthcare | 0.53% | +0.27% | +25.32% | |
| 42 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.44% | -0.44% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | +2.7% | +10.99% | Add |
| 2 | PFE | Pfizer Inc | +2.4% | +26.97% | Add |
| 3 | ZBH | Zimmer Biomet Holdings Inc | +0.6% | +17.63% | Add |
| 4 | BMRN | Biomarin Pharmaceutical Inc | +0.5% | +20.86% | Add |
| 5 | BIIB | Biogen Inc | +0.5% | +5.41% | Add |
| 6 | ELV | Elevance Health Inc | +0.4% | +35.08% | Add |
| 7 | SNDX | Syndax Pharmaceuticals Inc | +0.4% | +13.47% | Add |
| 8 | ASND | Ascendis Pharma A/S | +0.4% | +30.67% | Add |
| 9 | LNTH | Lantheus Holdings Inc | +0.3% | -0.51% | Trim |
| 10 | PTCT | Ptc Therapeutics Inc | +0.1% | +21.12% | Add |
| 11 | OGN | Organon & Co | 0% | +25.32% | Add |
| 12 | GEHC | GE Healthcare Technology | 0% | +10.51% | Add |
| 13 | BIO | Bio-rad Laboratories-a | -0.1% | — | Unchanged |
| 14 | TNDM | Tandem Diabetes Care Inc | -0.1% | — | Unchanged |
| 15 | MDT | Medtronic plc | -0.2% | +4.09% | Add |
| 16 | CAH | Cardinal Health Inc | -0.2% | -11.38% | Trim |
| 17 | KURA | Kura Oncology Inc | -0.3% | -9.66% | Trim |
| 18 | DXCM | Dexcom Inc | -0.3% | -26.27% | Trim |
| 19 | IONS | Ionis Pharmaceuticals Inc | -0.3% | -8.38% | Trim |
| 20 | LH | Labcorp Holdings Inc | -0.4% | -29.61% | Trim |
| 21 | CRNX | Crinetics Pharmaceuticals In | -0.4% | -18.09% | Trim |
| 22 | INCY | Incyte CORP | -0.5% | -8.35% | Trim |
| 23 | AVTR | Avantor Inc | -0.5% | — | Unchanged |
| 24 | BRKR | Bruker CORP | -0.6% | -0.27% | Trim |
| 25 | AMGN | Amgen Inc | -0.6% | -22.64% | Trim |
| 26 | EW | Edwards Lifesciences CORP | -0.7% | -37.34% | Trim |
| 27 | CVS | Cvs Health CORP | -0.9% | -23.80% | Trim |
| 28 | CNC | Centene CORP | -1.2% | -37.08% | Trim |
| 29 | MRK | Merck & Co. Inc. | -1.3% | -28.41% | Trim |
| 30 | BDX | Becton Dickinson And Co | -2.8% | -37.59% | Trim |
| 31 | GILD | Gilead Sciences Inc | -3.2% | -69.82% | Trim |
| 32 | TMO | Thermo Fisher Scientific Inc | — | EXIT | Sold out |
| 33 | UNH | Unitedhealth Group Inc | — | NEW | New buy |
| 34 | ABT | Abbott Laboratories | — | NEW | New buy |
| 35 | IQV | Iqvia Holdings Inc | — | NEW | New buy |
| 36 | QGEN | Qiagen N.V. | — | NEW | New buy |
| 37 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 38 | HCA | Hca Healthcare Inc | — | EXIT | Sold out |
| 39 | HUM | Humana Inc | — | NEW | New buy |
| 40 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 41 | IOVA | Iovance Biotherapeutics Inc | — | NEW | New buy |
| 42 | DNLI | Denali Therapeutics Inc | — | NEW | New buy |
| 43 | ARDX | Ardelyx Inc | — | NEW | New buy |
| 44 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 45 | CGON | Cg Oncology Inc | — | EXIT | Sold out |
| 46 | CERT | Certara Inc | — | EXIT | Sold out |
| 47 | ARWR | Arrowhead Pharmaceuticals In | — | NEW | New buy |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 42 disclosed positions in Q1 2026.
During Q1 2026, Sector Gamma As's top holdings by market value included BMY (11.9%)、MRK (7.4%)、PFE (7.2%). The largest single position, BMY, represented 11.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
UNH
市值: $9.9M
Top Position Liquidated / Trimmed
TMO
前期市值: $12.6M
In Q1 2026, Sector Gamma As made 44 total portfolio adjustments, initiating 11 new buys, adding to 12 positions, trimming 16 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.